Corcept Therapeutics Incorporated
CORT
$33.04
-$0.27-0.80%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -2.66% | 6.79% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -2.66% | 6.79% | |||
| Cost of Revenue | -44.63% | 33.88% | |||
| Gross Profit | -1.71% | 6.31% | |||
| SG&A Expenses | 5.05% | 19.38% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.11% | 17.68% | |||
| Operating Income | -56.09% | -61.69% | |||
| Income Before Tax | -34.99% | -51.90% | |||
| Income Tax Expenses | -224.93% | -28.00% | |||
| Earnings from Continuing Operations | 23.49% | -44.04% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 23.49% | -44.04% | |||
| EBIT | -56.09% | -61.69% | |||
| EBITDA | -54.55% | -61.03% | |||
| EPS Basic | 23.26% | -43.74% | |||
| Normalized Basic EPS | -35.11% | -51.66% | |||
| EPS Diluted | 25.19% | -44.83% | |||
| Normalized Diluted EPS | -35.21% | -51.46% | |||
| Average Basic Shares Outstanding | 0.14% | -0.54% | |||
| Average Diluted Shares Outstanding | 0.35% | -0.87% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||